CD40 expression on graft infiltrates and parenchymal CD154 (CD40L) induction in human chronic renal allograft rejection  by Gaweco, Anderson S. et al.
Kidney International, Vol. 55 (1999), pp. 1543–1552
CD40 expression on graft infiltrates and parenchymal CD154
(CD40L) induction in human chronic renal allograft rejection
ANDERSON S. GAWECO, BONNIE L. MITCHELL, BRUCE A. LUCAS, KENNETH D. MCCLATCHEY,
and DAVID H. VAN THIEL
Liver Transplant Program, Departments of Medicine, Pathology, and Surgery, Loyola University Medical Center,
Loyola University Chicago, Maywood, Illinois; Department of Pathology and Laboratory Medicine, VA Medical Center,
and Departments of Pathology and Urology, University of Kentucky Medical Center, Lexington, Kentucky, USA
the potential contributory role of an interaction between CD401CD40 expression on graft infiltrates and parenchymal CD154
graft-destructive effector T cells and macrophages with CD1541(CD40L) induction in human chronic renal allograft rejection.
Background. CD40-CD154 (CD40L) costimulatory signal- renal allograft parenchymal cells in the development of chronic
ing plays a pivotal role in the effector mechanisms of transplant renal allograft rejection.
graft rejection. In animal models, CD40-CD154 blockade in-
duces long-term graft acceptance concurrent with an absence
of chronic rejection (CR) lesions. Given the critical importance
of CD40-CD154 interactions in the development of chronic Kidney transplantation (KTx) has become an estab-
transplant allograft rejection, the relevance of in situ CD40
lished therapeutic procedure for end-stage renal diseaseand CD154 expression was assessed in human chronic renal
(ESRD). Chronic rejection (CR) remains a major causeallograft rejection.
Methods. The expression of CD40, CD154, CD68, and T-cell of late graft failure [1]. The underlying pathogenetic mech-
receptor (TCR)a/b was analyzed by immunohistochemistry. anisms of chronic allograft rejection remain ill-defined.
Serial cryostat sections of snap-frozen core renal allograft
Worse yet, only limited data are available in humanbiopsies were obtained from 30 renal transplant patients.
allograft situations. However, several experimental sys-Biopsy specimens received diagnoses of CR (N 5 23) according
to the Banff classification and were compared with controls tems have been established that enable studies of renal,
(N 5 7) consisting of stable allografts and normal kidney tissue. cardiac, and vascular allografts to be performed in animal
Results. Striking CD40 staining of graft cellular infiltrates
models of CR [2–4]. Current concepts of CR obtained(P 5 0.016) was observed in renal allografts with CR compared
from such experimental data implicate a multifactorialwith controls. The CD401 cellular infiltrates in CR were pre-
dominantly TCRa/b1 T cells and some CD681 macrophages. pathogenesis that involves both alloantigen-dependent
These findings were contrasted by the low-level CD40 expres- and -independent mechanisms [3, 5–8].
sion detected in glomeruli and tubules of CR and controls.
The important role of costimulatory signaling in theHowever, glomerular induction of CD154 was observed in CR
alloimmune response is well documented. Effector cellallografts (P 5 0.028) as compared with controls. CD154 immu-
noreactivity was demonstrated on glomerular endothelial, epi- activation is tightly regulated by signaling mechanisms
thelial, and mesangial cells. Moderate CD154 expression was following Ag-specific T-cell activation: signal 1 throughdetected on tubular epithelial cells, and only weak CD154
engagement of the T-cell receptor (TCR) with the pep-immunoreactivity was observed on the infiltrates in isolated
CR cases. tide-major histocompatibility complex on the antigen-
Conclusion. In human chronic renal allograft rejection, CD40 presenting cell and signal 2 through interactions of co-
is expressed on graft-infiltrating cells of the T cell and macro- stimulatory accessory molecules. Recent evidence hasphage compartments. CD154 expression is induced on glomer-
implicated the CD28/B7 and the CD40/CD154 (CD40L)ular and tubular epithelial cells during CR, demonstrating an-
other novel source of CD154 expression. The data substantiate pathways in allograft rejection. Inhibition of the CD28/B7
pathway prolongs allograft survival [9, 10]. More inter-
estingly, however, are recent reports of the induction of
long-term graft acceptance concurrent with an absenceKey words: transplantation, graft rejection, signaling, CD40/CD154,
of CR lesions by simultaneously blocking both CD28/B7alloimmune response, end-stage renal disease, chronic rejection.
and CD40/CD154 pathways [11–14]. Given the critical role
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Table 1. CD40 and CD154 staining intensity scores of chronic rejecting renal allografts
CD40 staining intensity scored CD154 staining intensity scored
Sampling date
Sample days after Tx CAN score Infiltrates Tubules Glomeruli Infiltrates Tubules Glomeruli
1 364 5 0 0 1 2 1
2 3968 7 3 2 0 0 1 2
3 1065 5 3 1 1
4 533 8 2 2 0 1 2
5 5886 6b 3 3 0 0 0 1
6 924 8 3 1 1 0 1 1
7 —a 12 3 3 1 0 0 3
8 —a 11 0 0 0 0 0 0
9 1326 7 1 2 1 0 0 3
10 3657 7 2 0
11 8725 12 3 0 1
12 428 5 1 0 3 1
13 476 —c 1 0 2 3
14 3290 4 1 1 0 0 3 3
15 747 6 1 0 0 2
16 1123 2 0 0 0 0 3 3
17 1231 7 2 1 2 3
18 755 5 3 0 0 1 3 3
19 688 2 3 1 0 3 0 1
20 5863 9 1 1 0 0 3 3
21 473 8 3 2 0 0 3 2
22 4862 4 3 0 3 1
23 167 5 1 0
a No available data
b No glomeruli and vascular structures identified on H&E slide
c No available H&E slides for CAN score evaluation
d Blank space denotes no corresponding structures identified on frozen-sections for analysis
METHODS post-transplant period (mean days post-transplant, 2378;
range 167 to 8725; Table 1), and indication for biopsyRenal allograft specimens
included a slowly rising serum creatinine concentration.Kidney biopsies obtained from 30 KTx patients at the
Stable renal allograft biopsies in the control group con-University of Kentucky Transplant Center were col-
sisted of post-transplant protocol biopsies.lected and immediately snap frozen in methylbutane.
Immunohistochemical analysis was performed on the Immunohistochemistry
kidney allograft biopsies obtained from KTx patients
CD40 and CD154 expression was analyzed by immu-with CR as the experimental group (N 5 23). Six stable
nohistochemistry on serial cryostat sections of snap-fro-renal allograft biopsies diagnosed as no rejection from
zen kidney tissue. Immunostaining was performed usingKTx patients and one normal kidney obtained at autopsy
an indirect immunoperoxidase procedure with the Vec-served as the controls (N 5 7). The diagnosis of CR and
tastain Elite ABC Kit (Vector, Burlingame, CA, USA).no rejection was based on criteria used as part of the
Kidney biopsies were embedded in optimal cutting tem-Banff classification [15, 16]. Histological data of the ex-
perature (OCT) compound and snap frozen in dry ice/perimental group are presented as chronic allograft ne-
methylbutane during sampling. Five-micrometer cryo-phropathy scores based on the Third Banff Conference
stat sections were mounted on glass slides. Followingon renal allograft pathology (Table 1) [16]. The individ-
paraformaldehyde fixation, endogenous peroxidase wasual chronic allograft nephropathy score was obtained by
blocked using 0.3% H2O2/methanol, and the slides werethe sum of each lesion quantitation scores of transplant
washed in phosphate-buffered saline (PBS). For CD154glomerulopathy (cg), interstitial fibrosis (ci), tubular at-
staining, quenching of endogenous peroxidase was per-rophy (ct), and vascular changes (cv). Twenty-two of the
formed by incubation in glucose oxidase/glucose/sodiumKTx patients were treated with the cyclosporine A-based
azide solution for one hour, followed by PBS washingimmunosuppressive regimen, which included azathio-
[17]. Tissue sections were incubated with 5% horse se-prine and methylprednisolone. Three KTx patients re-
rum for one hour, followed by blocking of endogenousceived the FK506-based regimen, which also included
biotin with the Avidin/Biotin blocking kit (Vector). Theazathioprine and methylprednisolone. Five KTx patients
slides were then incubated overnight with monoclonalwere treated with azathioprine and methylprednisolone
antibodies (mAbs) directed against human CD40 (clonebut without either cyclosporine A or FK506. Renal allo-
graft biopsies in the CR group were obtained late in the mAb89, mouse IgG1, diluted 1:150; Immunotech, West-
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Table 2. Mean staining intensity scores of CD40 immunoreactivity in chronic rejecting human kidney allografts and controls
Infiltratesa Tubules Glomeruli Vessels Fibroblasts
CD40
CR (N 5 23) 1.93860.306b 1.07660.198 0.28760.111 0 0
Controls (N 5 7) 0 1.50060.373 0.33360.167 0 —c
CD154
CR (N 5 23) 0.36760.221 1.42960.283 1.85360.274d 0.27860.182 0
Controls (N 5 7) 0 0.77860.290 0.71460.376 0 —c
a Mean staining intensity 6 sem
b P 5 0.016 vs. controls
c Fibroblasts in areas of fibrosis were assessed in CR that were not present in controls
d P 5 0.028 vs. controls
brook, ME, USA) and CD154 (clone TRAP1, mouse mean staining intensity was performed using the Stu-
dent’s t-test. The correlation of CD40 and CD154 stain-IgG1, diluted to 1:200; Pharmingen, San Diego, CA,
USA). Tissue sections were washed in PBS buffer and ing distribution with staining intensity of every structural
compartment in each individual biopsy was analyzed bysubsequently incubated with biotinylated horse anti-
mouse IgG and avidin-biotin-horseradish peroxidase. linear regression. All statistical analyses were performed
using SigmaStatt software. A P value of less than 0.05Sections for CD154 staining were subjected to tyramide
signal amplification (discussed later in this article) prior was considered significant.
to incubation with chromogen. Chromogenic reaction
was developed using aminoethyl carbonate (AEC) and
RESULTS
was counterstained with Mayer’s hematoxylin. Serial sec-
CD40 expressiontions of snap-frozen renal allograft biopsies from the
CR group were stained with anti-CD68 (clone EMB11, Moderate CD40 staining of graft infiltrates was de-
tected in CR (1.938 6 0.306, mean staining intensitymouse IgG1, diluted 1:200; Dako, Carpinteria, CA,
USA) as a marker for macrophages and anti-TCRa/b score 6 sem, P 5 0.016; Tables 1 and 2; Figs. 1 and 2),
which contrasted to the absence of CD40 expression on(clone bF1, mouse IgG1, diluted 1:100; Endogen, Wo-
burn, MA, USA) as a marker for T cells, as described the scanty infiltrates present in control specimens. The
estimated mean distribution (6 sem) of CD40 expressionearlier here, to identify the phenotype of the CD401
graft infiltrates in the CR group. on graft cellular infiltrates in CR allografts was at 60%
(6 7%) and ranged from 10 to 100%. The extent of
Tyramide signal amplification CD40 staining on graft infiltrates of CR correlated with
the CD40 staining intensity scores (R 5 0.854, P ,Cryostat sections for CD154 and TCRa/b staining
were subjected to a tyramide signal amplification step 0.001). CD401 infiltrates were seen around areas of
CD1541 tubules and glomeruli (discussed later here).using a commercially available amplification kit (New
England Nuclear, Boston, MA, USA) according to the Moderate CD40 staining of proximal tubules and a few
distal tubules was similarly demonstrated in both CRmanufacturer’s specifications. After incubation in avidin-
biotin-horseradish peroxidase and PBS wash, sections (1.076 6 0.198) and controls (1.500 6 0.373). Only sparse
glomerular CD40 expression in isolated cases of CRwere incubated for 10 minutes in biotinyl tyramide solu-
tion and washed in PBS. Slides were then incubated (0.287 6 0.111) and controls (0.333 6 0.167) was de-
tected. No CD40 immunoreactivity was detected on fi-in streptavidin-horseradish peroxidase for 30 minutes
followed by a PBS wash. Chromogen was added and broblasts in areas of interstitial fibrosis and in the vascu-
lature.counterstained as described earlier.
Data analysis Serial anti-CD68 and anti-TCRa/b staining of chronic
rejection specimensImmunohistochemical sections were assessed blindly
by two independent observers (A.S.G. and B.L.M.). The To determine the phenotype of CD401 graft-infiltrat-
ing mononuclear cells in CR allografts, sequential stain-staining intensity was semiquantitatively scored (0 5 no
staining, 1 5 weak, 2 5 moderate, 3 5 strong), and the ing with anti-CD68 and anti-TCRa/b mAbs were per-
formed on serial sections of eight CR specimens. Thestaining distribution (percentage estimate of positivity)
in each structural compartment was assessed. The follow- CD401 cellular infiltrates were predominantly TCRa/b1
with a mean (6 sd) estimated distribution of 73% (6 5)ing specific compartments were assessed: glomeruli, tu-
bules, vasculature, infiltrates, and fibroblasts in areas of (range 10 to 50%, P , 0.001) compared with only 27%
(6 5, range 50 to 90%), which were CD681 (Fig. 2).interstitial fibrosis. A statistical analysis comparing the
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Fig. 1. CD40 expression on mononuclear cellular infiltrates in repre-
sentative chronic rejection (CR) allograft biopsy of patient 2. AEC,
Mayer’s hematoxylin, magnification 3400.
Fig. 2. Serial anti-CD68 and anti-TCRa/b immunostaining demonstrating CD401 T cells and macrophages. Intense CD40 expression on graft
cellular infiltrates in a representative chronic rejection (CR) allograft biopsy (A, magnification 3100; D, magnification 3400). Sequential staining
of corresponding serial sections with anti-TCRa/b (B, magnification 3100; E, magnification 3400) and anti-CD68 mAbs (C, magnification 3100;
F, magnification 3400). AEC, Mayer’s hematoxylin.
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Fig. 2. continued
CD154 expression phages, dendritic cells, and parenchymal cells [18–21]. In
chronic renal allograft rejection, the findings presentedEnhanced CD154 expression was detected in the glo-
demonstrate CD40 expression on graft infiltrating cellsmeruli of CR (1.853 6 0.274, mean intensity 6 sem, P 5
of the macrophage and T-cell compartments. Denton et0.028; Tables 1 and 2), which contrasted to that of the
al have shown CD40 expression on infiltrating leukocytescontrols (0.6714 6 0.376). CD154 immunoreactivity was
in acute rejecting human renal allografts [22]. These datadetected on glomerular endothelial, mesangial, and epi-
are in contrast to the rare CD40 expression by controlthelial cells of almost all CR specimens (Fig. 3). The
groups reported using normal human kidney tissue andextent of CD154 staining in glomerular structures corre-
nonrejecting kidney allografts [23, 24]. The observed tu-lated with the staining intensity scores of CD154 (R 5
bular expression of CD40 may play a yet undefined role0.689, P , 0.001). A positive trend was observed in
in kidney function, as it has been demonstrated to influ-the moderate tubular CD154 immunoreactivity (1.429 6
ence cell growth and survival. The data presented are in0.283; Fig. 4), mostly seen in atrophic and intact proximal
line with previous studies demonstrating the constitutivetubules and in a few distal tubules in CR compared with
CD40 expression on tubular epithelial cells in culturecontrols (0.778 6 0.290). Only weak CD154 expression
and in normal kidney, inflammatory renal diseases, andin the vasculature and infiltrates was detected in three
acute rejecting renal allografts [22, 23, 25].isolated cases of CR, which was absent in all control
The finding of enhanced CD154 expression predomi-cases. No CD154 staining was detected on fibroblasts in
nantly in renal parenchyma of kidney allografts manifest-fibrotic areas of CR.
ing histologic evidence of CR extends the broad cellular
expression pattern of CD154. CD154, the ligand for
DISCUSSION CD40, was initially thought to be expressed exclusively
on activated T cells. Recent reports, however, have docu-The CD40 receptor belongs to the tumor necrosis fac-
tor receptor superfamily and is expressed on a variety mented a wide cellular distribution of CD154 expression
on human dendritic cells [26], B cells [26], endothelialof cell types, including B cells, T cells, monocytes/macro-
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Fig. 3. Glomerular CD154 expression demonstrating intense mesangial (A, arrows), epithelial (B, arrowheads), and endothelial staining (C). (D)
The absence of glomerular CD154 expression in a renal allograft biopsy with stable graft function. Magnification 3400, AEC, Mayer’s hematoxylin.
cells, renal tubular epithelium [23], smooth muscle cells, support and confirm their findings at the protein expres-
sion level of a lack of CD154 expression in the absenceand macrophages of atherosclerotic lesions [27], as well
as acute rejecting heart allografts [28]. In human chronic of rejection and in immunologic quiescence. The minimal
CD154 expression detected on the minor graft infiltrates,renal allograft rejection, CD154 is induced not only on
glomerular microvascular endothelial cells but on glo- albeit seen only in cases of CR, suggests a different
important source of CD154 in CR other than activatedmerular epithelial, mesangial cells, and tubular epithelial
cells as well. The observed de novo CD154 expression T cells alone. The marked de novo expression of CD154
on glomerular and tubular structures in chronic rejectingduring CR stands in contrast to the relative absence of
CD154 expression in nonrejecting kidney allografts and renal allografts extends the available current data rela-
tive to the broad cellular distribution of CD154 and itsnormal kidney tissue. Zheng et al have recently reported
the up-regulation of CD154 gene transcripts in acute potential importance in the pathogenesis of chronic kid-
ney graft rejection.rejecting human renal allografts [24]. In accordance with
their findings of low-level CD154 gene activation in non- A stimulation-dependent soluble form of CD154
(sCD154) exists and, like the membrane-bound CD154,rejecting renal allografts and normal kidney, these data
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Fig. 4. Strong CD154 immunoreactivity in proximal tubules of a chronic rejection (CR) biopsy (A, magnification 3100; B, magnification 3400).
(C) The incubation of a serial section of the same biopsy (A, B) with isotype-matched Ab as negative control (magnification 3100). (D) The
absence of CD154 immunoreactivity in proximal tubules of a control renal allograft (magnification 3100). AEC, Mayer’s hematoxylin.
possesses functional biological properties [29, 30]. Acti- cells, and strongly contrasts with the enhanced CD154
expression on glomerular and tubular structures. Fur-vated T cells have been reported to release sCD154 in
vitro through intracellular proteolytic processing that thermore, the known concomitant membrane CD154 ex-
pression and sCD154 release strongly argue that sCD154parallels the kinetics of cell surface CD154 expression
[29, 31]. The observed CD154 immunoreactivity on glo- is being released in the relative absence of surface CD154
expression on infiltrating mononuclear cells during CR.merular and tubular epithelial cells therefore implicates
the potential immunolocalization of sCD154 bound to The sparse CD40 expression observed in glomeruli and
tubules could be due to a CD154-mediated negative reg-CD40 on renal parenchymal cells during CR. However,
the data presented refute the argument of a potential ulatory mechanism. sCD154 down-regulates CD40 ex-
pression of bystander cells in an autocrine and paracrinecross-reactivity with a-CD154 mAb. False immunoreac-
tivity against shed CD154 bound to CD40 is unlikely, as manner in a cytokine-like fashion [29]. Given the en-
hanced glomerular and tubular CD154 expression, it isonly minimal CD40 expression was observed on the same
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probable that concomitant sCD154 release by these same effects of CD40-mediated signaling through CD154
treatment have been directly attributed to NF-kB activa-cells may act to repress or inhibit the expression of CD40.
An important consequence of CD40 interaction on tion, which is associated with IkB degradation [40].
Studies of chronic allograft rejection pathology haveantigen-presenting cells with CD154 on graft-specific
CD41 T cells involves regulatory mechanisms crucial to emphasized the transplant vasculopathy lesions that are
common to all solid organ allografts. In CR of the allo-the destructive process of graft rejection. These include
the potentiation of antigen-presenting cell function and graft kidney, characteristic glomerular and tubular
changes occur. Current concepts of CR obtained fromT-cell priming, activation, and differentiation through
up-regulation of cell surface costimulatory molecules, experimental data provide evidence for a central role of
inflammatory mediators, which include cytokines andadhesion molecules, and provision of critical inflamma-
tory mediators and cytokines that all contribute to graft chemokines, and growth factors in several CR allograft
models [2–8], and are clearly observed in human renalrejection pathology. Of interest, however, is the possibil-
ity of a bidirectional modulation of CD40-CD154 signaling allografts as well [41–44]. In fact, selective therapeutic
intervention preventing the development of CR is associ-mechanisms that may contribute to the destructive ef-
fector mechanisms of CR. Both CD40 and CD154 have ated with the down-regulation of these inflammatory
mediator responses [45]. It is, therefore, tempting tobeen reported to be coexpressed in human cardiac allo-
grafts on both allograft endothelial cells and graft-infil- speculate that a consequence of CD40-CD154 interac-
tion not only leads to provision of critical inflammatorytrating T lymphocytes during acute rejection [28] and in
atherosclerotic lesions [27]. In line with these findings, mediators like proinflammatory cytokines and chemo-
kines by allograft-specific cellular effector cells, but, alsothese data demonstrating CD40 expression on recipient
effector cells and CD154 induction on donor allografts by renal epithelial cells of the allograft. In addition to
its role as a cognate ligand in CD40-mediated events,implicate a direct cross-talk between CD401 T cells and
macrophages with CD1541 glomerular and tubular epi- current data suggest that direct CD154 signaling may
thelial cells. independently contribute to signal-transducing events
The effects of CD40 ligation include not only the in- through a direct costimulatory receptor function [46]. In
duction of major histocompatibility complex and costi- fact, directly engaging CD154 leads to cytokine produc-
mulatory molecule B7 expression, but also the provision tion [47, 48]. This assumption would not be surprising
of inflammatory cytokines and chemokines by mononu- as glomerular and tubular epithelial cells are known to
clear cells [23, 27, 32]. A possible CD40 cross-linking on synthesize cytokines and chemokines directly in the en-
CD401-infiltrating graft lymphocytes and macrophages suing stages of chronic renal allograft rejection [49].
by the de novo expressed CD154 on glomerular and Evidence has already been presented demonstrating
tubular epithelial cells could therefore induce the produc- the importance of blocking the CD40/CD154 costimula-
tion of inflammatory mediators known to be elaborated tory pathway in the induction of long-term allograft sur-
during CR. The sustained intragraft release of these po- vival and prevention of chronic allograft rejection in
tentially graft destructive mediators may play a critical animal models [11, 13, 14]. The novel data presented in
role in the pathology of chronic allograft rejection. The this study of de novo CD154 expression on renal allograft
administration of CD154, which leads to CD40 ligation, parenchyma and graft-infiltrating CD401 T cells and
induces potent biological effects on T cells and mono- macrophages during CR may help elucidate the destruc-
cytes promoting optimal activation, proliferation, and tive mechanisms of CD40/CD154 interactions that may
cytokine production [33–35]. The production of these contribute to the development of human chronic renal
mediators by CD401 graft infiltrates is likely, as these allograft rejection.
cells have been demonstrated to produce inflammatory
cytokines following direct CD40 engagement [23, 27, 32].
NOTE ADDED IN PROOFIn support of this hypothesis, the disruption of CD40/
The upregulated CD154 expression on Kupffer cellsCD154 interactions that leads to the prevention of graft
has recently been reported in human liver allografts dur-rejection is associated with the inhibition of proinflam-
ing chronic ductopenic rejection [Gaweco AS, Wiesnermatory and T helper type 1 (Th1) cytokines [11, 36]. Of
RH, Yong S, Krom R, Porayko M, Chejfec G, McClat-critical importance, moreover, are recent reports attrib-
chey KD, Van Thiel DH: CD40L (CD154) expressionuting CD40 signaling in preventing apoptosis [37]. CD40
in human liver allografts during chronic ductopenic re-engagement promotes the viability of mononuclear cells
jection. Liver Transpl Surg 5:1–7, 1999].through antiapoptotic mechanisms [32, 37]. Recently,
CD40-mediated signaling has been reported to activate
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